Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Rheumatoid Arthritis · Calcium

Universal Integrated

Universal Integrated drug portfolio — 105 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
HILLSIDE, NJ, CN HQ
2006 Founded
304 Employees
NMPA registrant Type
Company details
Status
Public
HQ
HILLSIDE, NJ, CN
Founded
2006
Employees
304
Programs
89
Drugs
105
Patents
42
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Drug Pipeline

Universal Integrated pipeline

Portfolio lens on 105 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Universal Integrated drug portfolio — 105 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

105 compounds

  1. acyclovir sodium

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  2. amoxicillin

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  3. anesthesia

    Development asset linked to Universal Integrated in public FDA and regional records.

  4. anti-

    Development asset linked to Universal Integrated in public FDA and regional records.

  5. arthroplasty

    Development asset linked to Universal Integrated in public FDA and regional records.

  6. aspirin

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  7. autologous

    Development asset linked to Universal Integrated in public FDA and regional records.

  8. benzgalantamine gluconate

    US regulatory status: approved. Molecular target: Acetylcholinesterase.

    Target
    Acetylcholinesterase
    Mechanism
    Acetylcholinesterase inhibitor

  9. betamethasone valerate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  10. bleomycin

    Development asset linked to Universal Integrated in public FDA and regional records.

  11. calcium

    US regulatory status: approved.

  13. capsule

    Development asset linked to Universal Integrated in public FDA and regional records.

  14. car-t

    Development asset linked to Universal Integrated in public FDA and regional records.

  15. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  16. cells

    Development asset linked to Universal Integrated in public FDA and regional records.

  17. chloride

    Development asset linked to Universal Integrated in public FDA and regional records.

  18. citalopram

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  20. clomiphene citrate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha modulator

  21. cyproterone

    Development asset linked to Universal Integrated in public FDA and regional records.

  22. decoction

    Development asset linked to Universal Integrated in public FDA and regional records.

  23. donepezil

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.

    Mechanism
    Acetylcholinesterase inhibitor

  24. donepezil hydrochloride

    US regulatory status: approved. Molecular target: Acetylcholinesterase.

    Target
    Acetylcholinesterase
    Mechanism
    Acetylcholinesterase inhibitor

  27. erythromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  28. escitalopram

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  29. escitalopram oxalate

    US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.

    Target
    Sodium-dependent serotonin transporter
    Mechanism
    Serotonin transporter inhibitor

  30. estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  31. etanercept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  32. experimental

    Development asset linked to Universal Integrated in public FDA and regional records.

  33. formoterol

    Respiratory system (R03)

    Respiratory system (R03) compound in Universal Integrated's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.

    Mechanism
    Beta-2 adrenergic receptor agonist

  34. formoterol (fumarate)

    Respiratory system (R03)

    Respiratory system (R03) compound in Universal Integrated's portfolio. Molecular target: Beta-2 adrenergic receptor.

    Target
    Beta-2 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor agonist

  35. formoterol fumarate

    US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.

    Target
    Beta-2 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor agonist

  36. galantamine

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.

    Mechanism
    Acetylcholinesterase inhibitor

  37. glucagon hydrochloride

    US regulatory status: approved. Molecular target: Glucagon receptor.

    Target
    Glucagon receptor
    Mechanism
    Glucagon receptor agonist

  38. goserelin

    US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.

    Mechanism
    Gonadotropin-releasing hormone receptor agonist

  39. granule

    Development asset linked to Universal Integrated in public FDA and regional records.

  40. granules

    Development asset linked to Universal Integrated in public FDA and regional records.

  41. group

    Development asset linked to Universal Integrated in public FDA and regional records.

  42. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  43. high-dose

    Development asset linked to Universal Integrated in public FDA and regional records.

  44. immunocheckpoint

    Development asset linked to Universal Integrated in public FDA and regional records.

  45. infliximab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  46. inhibitor

    Development asset linked to Universal Integrated in public FDA and regional records.

  47. injectable

    Development asset linked to Universal Integrated in public FDA and regional records.

  48. injection

    Development asset linked to Universal Integrated in public FDA and regional records.

  49. insulin

    Development asset linked to Universal Integrated in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  50. insulin aspart recombinant

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  51. intensive

    Development asset linked to Universal Integrated in public FDA and regional records.

  52. interferon alfa-2b

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  53. intervention

    Development asset linked to Universal Integrated in public FDA and regional records.

  54. ixekizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-17A.

    Target
    Interleukin-17A
    Mechanism
    Interleukin 17A inhibitor

  55. loperamide

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  56. loperamide hydrochloride

    US regulatory status: approved. Molecular target: Mu-type opioid receptor.

    Target
    Mu-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  57. magnesium

    Development asset linked to Universal Integrated in public FDA and regional records.

  58. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  59. methylprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  60. methylprednisolone sodium succinate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  61. modified

    Development asset linked to Universal Integrated in public FDA and regional records.

  62. mometasone

    Development asset linked to Universal Integrated in public FDA and regional records.

  63. mometasone furoate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  64. monohydrate

    Development asset linked to Universal Integrated in public FDA and regional records.

  65. nacl

    Development asset linked to Universal Integrated in public FDA and regional records.

  66. nedosiran sodium

    US regulatory status: approved. Molecular target: L-lactate dehydrogenase A chain mRNA.

    Target
    L-lactate dehydrogenase A chain mRNA
    Mechanism
    L-lactate dehydrogenase A chain mRNA RNAi inhibitor

  67. normal

    Development asset linked to Universal Integrated in public FDA and regional records.

  68. ointment

    Development asset linked to Universal Integrated in public FDA and regional records.

  69. oxaliplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  70. peginterferon

    Development asset linked to Universal Integrated in public FDA and regional records.

  71. peginterferon alfa-2b

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  72. pegulicianine acetate

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  74. personalized

    Development asset linked to Universal Integrated in public FDA and regional records.

  75. placebo

    Development asset linked to Universal Integrated in public FDA and regional records.

  76. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  77. progesterone

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  78. propranolol

    Cardiovascular system (C07)

    Cardiovascular system (C07) compound in Universal Integrated's portfolio. Mechanism: Beta-1 adrenergic receptor antagonist.

    Mechanism
    Beta-1 adrenergic receptor antagonist

  79. qing

    Development asset linked to Universal Integrated in public FDA and regional records.

  80. qishenyiqi

    Development asset linked to Universal Integrated in public FDA and regional records.

  81. rabeprazole

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Potassium-transporting ATPase inhibitor.

    Mechanism
    Potassium-transporting ATPase inhibitor

  82. rabeprazole sodium

    US regulatory status: approved. Molecular target: Potassium-transporting ATPase.

    Target
    Potassium-transporting ATPase
    Mechanism
    Potassium-transporting ATPase inhibitor

  83. radiation

    Development asset linked to Universal Integrated in public FDA and regional records.

  84. remicade

    Development asset linked to Universal Integrated in public FDA and regional records. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  85. ribavirin

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.

    Target
    Inosine-5'-monophosphate dehydrogenase 1
    Mechanism
    Inosine-5'-monophosphate dehydrogenase 1 inhibitor

  86. sevoflurane

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    Potassium channel subfamily K member 2 opener

  87. sibutramine hydrochloride

    US regulatory status: approved. Molecular target: Monoamine transporter.

    Target
    Monoamine transporter
    Mechanism
    Monoamine transporter inhibitor

  89. solution

    Development asset linked to Universal Integrated in public FDA and regional records.

  90. spray

    Development asset linked to Universal Integrated in public FDA and regional records.

  91. stro-

    Development asset linked to Universal Integrated in public FDA and regional records.

  92. t-cell

    Development asset linked to Universal Integrated in public FDA and regional records.

  93. tablet

    Development asset linked to Universal Integrated in public FDA and regional records.

  94. tablets

    Development asset linked to Universal Integrated in public FDA and regional records.

  96. temozolomide

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  97. therapy

    Development asset linked to Universal Integrated in public FDA and regional records.

  98. tiotropium

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.

    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  99. tirofiban

    Development asset linked to Universal Integrated in public FDA and regional records. Mechanism: Integrin alpha-IIb/beta-3 inhibitor.

    Mechanism
    Integrin alpha-IIb/beta-3 inhibitor

  100. tirofiban hydrochloride

    US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.

    Target
    Integrin alpha-IIb/beta-3
    Mechanism
    Integrin alpha-IIb/beta-3 inhibitor

  101. treatment

    Development asset linked to Universal Integrated in public FDA and regional records.

  102. triamcinolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  103. triamcinolone acetonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  104. urea

    US regulatory status: approved.

  105. western

    Development asset linked to Universal Integrated in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.